Loading...

Syros Pharmaceuticals, Inc.

SYRSNASDAQ
Healthcare
Biotechnology
$0.009
$-0.00(-10.00%)

Syros Pharmaceuticals, Inc. (SYRS) Stock Overview

Explore Syros Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 67.7/100

Key Financials

Market Cap241.5K
P/E Ratio-0.00
EPS (TTM)$-3.07
ROE-27.47%
Fundamental Analysis

AI Price Forecasts

1 Week$0.02
1 Month$0.29
3 Months$6.87
1 Year Target$1.48

SYRS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Syros Pharmaceuticals, Inc. (SYRS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 35.93, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1.48.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.00 and a market capitalization of 241.5K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

35.93RSI (14)
0.00MACD
39.37ADX
Stats data is not available for SYRSStats details for SYRS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations

Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$5.00
Average$5.00
High$5.00

Company Profile

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

CEO

James E. Bradner

Employees

68

Headquarters

35 CambridgePark Drive, Cambridge, MA

Founded

2016

Frequently Asked Questions

;